Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs. Conventional Two-Stage Hepatectomy (TSH) for Surgical Treatment of Marginally Resectable Colorectal Liver Metastases (CRLM) - A Multicentric, Randomized Controlled Trial

NCT02758977 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.

NCT NCT02758977
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02758977 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs. Conventional Two-Stage Hepatectomy (TSH) for Surgical Treatment of Marginally Resectable Colorectal Liver Metastases (CRLM) - A Multicentric, Randomized Controlled Trial
Lead sponsor
University of Zurich
Phase
Not applicable
Overall status
Unknown status
Start date
May 31, 2016
Completion date
Not reported
Enrollment
214 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer liver metastases, hepatectomy, liver diseases, liver neoplasms, malignant neoplasm of large intestine metastatic to liver, secondary malignant neoplasm of liver, surgery